Elias Pettersson

  • Content Count

  • Joined

  • Last visited

  • Days Won


Elias Pettersson last won the day on September 22 2019

Elias Pettersson had the most liked content!

Community Reputation

4,239 Gaming the system

About Elias Pettersson

  • Rank

Recent Profile Visitors

1,431 profile views
  1. It's all good Deb. Sorry, I've been busy with life so I'm stepping away from here for awhile. May join up for some poker later on so I can take back the chips you stole from me. Will come back once I return from Sweden and we get back to playing hockey again. Petey is out but will be back...
  2. I think I’m going to stick to just stealing your chips Deb. See you later...
  3. Very well said my friend, couldn't have said it any better myself...
  4. No blind faith isn't smart, I would agree with that. But I will certainly put more trust on Dr. Bonnie Henry who has led us to this point and has done a fantastic job over others who don't even have a medical background and are simply giving their opinions in this thread. You are definitely entitled to your opinion and I respect what you say, but at the end of the day if an actual decision has to be made then Dr. Bonnie Henry is the one to make it not us, and I trust her 100%...
  5. No you are not. The same people who said we should lock down are now saying we should open up. In both cases they are correct and are putting safety measures in place to safely re-open. The people who want to stay in lock down forever or until there is a vaccine are now going to start questioning Dr. Bonnie Henry and the government because it doesn't suit their argument. I have trusted Dr. Bonnie Henry from the beginning and I trust her 100% now.
  6. Yes that is right. ALL lives matter, including the people who are dying because of suicide, depression, drug overdoses and because they can't feed their families. Who said anything about treating the elderly badly? Most of the elderly who have died have been living in a senior's home. It's unfortunate the virus spread to those places but what are we supposed to do? They should be doing a better job at protecting seniors who live alone and who live in a long term care facility or senior's home. People going back to work is not putting those elderly people at risk. They need to be better protected by following the advice of Dr. Bonnie Henry. I have no idea what they are doing in those long term care facilities. Maybe the government should find out what their protocols are in how they deal with their patients and residents. Maybe an investigation needs to be done. Why are there so many outbreaks in these places? That question needs to be answered. If my parents were in a long term care home I would do everything humanly possible to try and protect them, so I would be the first one asking these questions.
  7. Yes you are wrong. The average age of death in BC is 86 years old. Only 2 people have died under the age of 70. This is coming from Dr. Bonnie Henry. You should watch her daily updates to get the most accurate information.
  8. It's not just about the kids or the 8 days. It's also about the parents being able to go back to work and feed their families. If they can get things going in June and understand what is needed in order to keep people safe then come September they will have an even better knowledge and grasp of how to handle this situation. We don't need to wait for September to re-open the Province. We can do it safely next month with all the proper measures put in place by Dr. Henry and the Provincial government. I trust their judgement. 3 more months of everyone simply staying at home will completely destroy this country for generations to come. JUST NOT WORTH THE RISK...
  9. With all due respect Bree going camping and seeing your family is not an essential service. Sending kids back to school in a safe way will allow daycare to open again and will allow parents to go back to work so they can feed their families. We can't shut down the economy forever and destroy the country because of a virus that has only killed 140 people in all of BC, most over the age of 70 or with a pre-existing condition. Young people deserve to have a life and not have their future lives ruined because of this virus. My parents would want me and the young people in this country to have a future. My parents have already lived a full life. Why would they want my life destroyed in order to try and protect them? All I hear in this thread is trying to protect the elderly and sick people. If I go out and try to have a life I am risking killing somebody's parents. Nothing but fear mongering in this thread for the past 2 1/2 months which is why I barely post in here anymore. Every life is important, not just your parents lives. People are dying of suicide, drug overdoses, depression because of this virus, it's not only the people actually getting the virus that are dying. People can't get surgeries that can save their lives. The economy is going into the tank. If we stay closed for 2 more months like this our economy may be permanently damaged. Is that the cost we are supposed to pay for this virus? To ruin the life of every young person out there and their future because somebody's parents might die if I decide to go outside? Are we supposed to wait for a vaccine before we can leave the house? That might take a year or more. You think anyone will be going back to their job in a year? You think those jobs will still be around? I think BC has done a great job in handling this whole situation. 140 people have died out of a population of over 5 million. That is absolutely phenomenal when you look at other areas of the country and other countries. I trust Dr. Bonnie Henry to do the right thing as she has done the right thing this whole time. If she says certain people can go back to work and kids can go back to school in a SAFE way then I trust her 100%. Dr. Henry has a plan to re-open BC in a safe way. It's already been outlined in detail. Enough with the fear mongering. Let's get back to work and start enjoying our lives again. We WILL get through this.
  10. https://news.columbia.edu/ultraviolet-technology-virus-covid-19-UV-light Could a New Ultraviolet Technology Fight the Spread of Coronavirus? Columbia researcher David Brenner believes far-UVC light—safe for humans, but lethal for viruses—could be a ‘game changer.’ A technique that zaps airborne viruses with a narrow-wavelength band of UV light shows promise for curtailing the person-to-person spread of COVID-19 in indoor public places. The technology, developed by Columbia University’s Center for Radiological Research, uses lamps that emit continuous, low doses of a particular wavelength of ultraviolet light, known as far-UVC, which can kill viruses and bacteria without harming human skin, eyes and other tissues, as is the problem with conventional UV light. “Far-UVC light has the potential to be a ‘game changer,’” said David Brenner, professor of radiation biophysics and director of the center. “It can be safely used in occupied public spaces, and it kills pathogens in the air before we can breathe them in.” The research team's experiments have shown far-UVC effective in eradicating two types of airborne seasonal coronaviruses (the ones that cause coughs and colds). The researchers are now testing the light against the SARS-CoV-2 virus in collaboration with Thomas Briese and W. Ian Lipkin of the Center for Infection and Immunity in a biosafety laboratory on Columbia's medical center campus, with encouraging results, Brenner said. The team previously found the method effective in inactivating the airborne H1N1 influenza virus, as well as drug-resistant bacteria. And multiple, long-term studies on animals and humans have confirmed that exposure to far-UVC does not cause damage to the skin or eyes. "Our system is a low-cost, safe solution to eradicating airborne viruses minutes after they've been breathed, coughed or sneezed into the air." If widely used in occupied public places, far-UVC technology has the potential to provide a powerful check on future epidemics and pandemics, Brenner said. He added that even when researchers develop a vaccine against the virus that causes COVID, it will not protect against the next novel virus. “Our system is a low-cost, safe solution to eradicating airborne viruses minutes after they've been breathed, coughed or sneezed into the air,” Brenner said. “Not only does it have the potential to prevent the global spread of the virus that causes COVID-19, but also future novel viruses, as well as more familiar viruses like influenza and measles.” Brenner envisions the use of safe overhead far-UVC lamps in a wide range of indoor public spaces. The technology, which can be easily retrofitted into existing light fixtures, he said, could be deployed in hospitals and doctors’ offices as well as schools, shelters, airports, airplanes and other transportation hubs. Scientists have known for decades that germicidal UV light (wavelength around 254 nm) has the capacity to kill viruses and bacteria. Hospitals and laboratories often use germicidal UV light to sterilize unoccupied rooms, as well as other equipment. But conventional germicidal UV light cannot be used in the presence of people as it can causes health problems to the skin and eyes. In contrast, far-UVC light, which has a very short wavelength (in the range from about 205 to 230 nm), cannot reach or damage living human cells. But these wavelengths can still penetrate and kill very small viruses and bacteria floating in the air or on surfaces. Far-UVC lamps are now in production by several companies, although ramping up to large-scale production, as well as approval by the Food and Drug Administration and Environmental Protection Agency, will take several months. At between $500 and $1000 per lamp, the lamps are relatively inexpensive, and once they are mass produced the prices would likely fall, Brenner said. “Far-UVC takes a fundamentally different tactic in the war against COVID-19,” Brenner said. “Most approaches focus on fighting the virus once it has gotten into the body. Far-UVC is one of the very few approaches that has the potential to prevent the spread of viruses before they enter the body.”
  11. So that is your excuse for not wanting to go head to head with Petey? I don’t blame you. Not many players want to take me on one on one really...
  12. https://www.worldhealth.net/news/cedars-sinai-use-uv-light-treat-covid-19 Cedars-Sinai To Use UV Light To Treat COVID-19 Ultraviolet therapy may be coming to a hospital near you to help treat COVID-19 developed by Cedars-Sinai hospital in Los Angeles. Healight Platform Technology has been exclusively licensed to Aytu BioScience Inc for worldwide commercial development and release which could mean that hospitals around the globe may soon adopt this approach. According to some reports this method has been billed as being a potential “first-in-class treatment for coronavirus and other respiratory infections,” that utilizes proprietary methods of administering intermittent UVA light using a novel endotracheal device. Preclinical study findings are suggesting that this approach has the potential to help eradicate the spread of this COVID-19 outbreak, as well as “a wide range of viruses and bacteria, inclusive of coronavirus.” A team from the Medically Associated Science and Technology Program at Cedars-Sinai led by Dr. Mark Pimental, MD have been developing Healight since 2016, and it has a growing body of evidence demonstrating its efficacy as both an antiviral and an antibacterial treatment. There have been rumors of talks with the FDA about the development of a near term path that could enable early use of this technology to help the COVID-19 patients who are suffering in ICUs, and it may also be useful in treating ventilator associated pneumonia, or VAP. "Our team has shown that administering a specific spectrum of UV-A light can eradicate viruses in infected human cells (including coronavirus) and bacteria in the area while preserving healthy cells," stated Dr. Pimentel of Cedars-Sinai. Ali Rezaie, MD, one of the inventors of this technology states, "Our lab at Cedars-Sinai has extensively studied the effects of this unique technology on bacteria and viruses. Based on our findings we believe this therapeutic approach has the potential to significantly impact the high morbidity and mortality of coronavirus-infected patients and patients infected with other respiratory pathogens. We are looking forward to partnering with Aytu BioScience to move this technology forward for the benefit of patients all over the world." The FDA, Aytu, and Cedars-Sinai are rumored to be working together towards developing a plan for the expedited regulatory approval of Healight to be used against the continued battle against the global COVID-19 outbreak. Those critical ill with this virus may benefit from use of this minimally invasive treatment approach. Around the globe many hospitals are already using UV light to help clean surfaces and disinfect rooms where COVID-19 patients have been treated, extending the use of such technology to the direct treatment of the virus in patients would appear to be the next logical step. Natural UV light from the sun appears to be able to destroy most harmful bacteria on the skin as well as viruses and other microbes, similar benefit could also potentially be gained from using artificial UV rays generated by medical devices, and this is what Aytu and Cedars-Sinai are hoping will be widely implemented around the globe. “We are honored to be partnering with Cedars-Sinai as we believe the Healight therapeutic platform has the potential to help many patients during this coronavirus pandemic and beyond.This first-in-class technology has the potential to be a game changer for clinicians treating patients infected with coronavirus and other respiratory conditions, and our team is working tirelessly alongside the Cedars-Sinai team to determine the safety and effectiveness of this device in humans,” says Josh Disbrow, Chairman and CEO of Aytu BioScience.
  13. https://www.nih.gov/news-events/news-releases/nih-begins-clinical-trial-hydroxychloroquine-azithromycin-treat-covid-19 NIH begins clinical trial of hydroxychloroquine and azithromycin to treat COVID-19 Study enrolling adults with mild to moderate COVID-19 in the United States. A clinical trial has begun to evaluate whether the malaria drug hydroxychloroquine, given together with the antibiotic azithromycin, can prevent hospitalization and death from coronavirus disease 2019 (COVID-19). The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is sponsoring the trial, which is being conducted by the NIAID-funded AIDS Clinical Trials Group (ACTG). Teva Pharmaceuticals is donating medications for the study. The Phase 2b trial will enroll approximately 2,000 adults at participating ACTG sites(link is external) across the United States. Study participants must have confirmed infection with SARS-CoV-2, the virus that causes COVID-19, and be experiencing fever, cough and/or shortness of breath. The investigators anticipate that many of those enrolled will be 60 years of age or older or have a comorbidity associated with developing serious complications from COVID-19, such as cardiovascular disease or diabetes. Participants will be randomly assigned to receive short-term treatment with either hydroxychloroquine and azithromycin or matching placebos. People living with HIV and pregnant and breastfeeding women also are eligible to participate in the study. The first participant enrolled today in San Diego, California. “We urgently need a safe and effective treatment for COVID-19. Repurposing existing drugs is an attractive option because these medications have undergone extensive testing, allowing them to move quickly into clinical trials and accelerating their potential approval for COVID-19 treatment,” said NIAID Director Anthony S. Fauci, M.D. “Although there is anecdotal evidence that hydroxychloroquine and azithromycin may benefit people with COVID-19, we need solid data from a large randomized, controlled clinical trial to determine whether this experimental treatment is safe and can improve clinical outcomes.” As of May 13, the World Health Organization (WHO)(link is external) has reported 4.17 million cases of and 287,399 deaths from COVID-19 worldwide. In the United States, 1.36 million confirmed COVID-19 cases and 82,246 deaths have been reported as of May 13, according to the Centers for Disease Control and Prevention (CDC)(link is external). Currently, there are no specific therapeutics approved by the U.S. Food and Drug Administration to treat people with COVID-19. Hydroxychloroquine is FDA-approved to prevent and treat malaria, as well as to treat the autoimmune diseases rheumatoid arthritis and lupus. Some preliminary reports have suggested that hydroxychloroquine, alone or in combination with the FDA-approved antibiotic azithromycin, may benefit people with COVID-19. Numerous clinical trials are planned or underway, including a recently launched study supported by NIH’s National Heart, Lung and Blood Institute evaluating the safety and effectiveness of hydroxychloroquine for treatment of adults hospitalized with COVID-19. On March 28, FDA issued an Emergency Use Authorization(link is external) (EUA) to allow hydroxychloroquine and medical-grade chloroquine to be distributed from the Strategic National Stockpile and prescribed by doctors to hospitalized adolescents and adults with COVID-19, as appropriate, when a clinical trial is not available or feasible. Participants will record their symptoms, adherence to treatment, and major events such as hospitalizations in a diary for 20 days. Study staff will follow up with participants by telephone during this period. When possible, participants will come to the clinical research site for an in-person visit at day 20. Additional follow-ups will be conducted by telephone three and six months after treatment starts. The main objective of the study is to determine whether hydroxychloroquine and azithromycin can prevent hospitalization and death due to COVID-19. Additionally, investigators will evaluate the safety and tolerability of the experimental treatment for people with SARS-CoV-2 infection. While hydroxychloroquine and azithromycin are both considered safe in most people, they can cause side effects ranging from headache and nausea to, rarely, heart rhythm problems that can be life-threatening. Because of the risk of heart problems when hydroxychloroquine is used alone or combined with azithromycin, FDA cautions that use of hydroxychloroquine for COVID-19 should be limited to clinical trials or for treating certain hospitalized patients under EUA(link is external) so clinicians can monitor patients for adverse effects. “This study will provide key data to aid responses to the COVID-19 pandemic,” said ACTG Chair Judith Currier, M.D., of the University of California, Los Angeles. “We are pleased to be able to leverage ACTG’s existing infrastructure for HIV treatment clinical trials to quickly implement this important study.” The study team is led by Protocol Chair Davey Smith, M.D., of the University of California, San Diego. David Wohl, M.D., of the University of North Carolina at Chapel Hill, and Kara W. Chew, M.D., and Eric S. Daar, M.D., both of the University of California, Los Angeles, serve as protocol vice-chairs. The trial is expected to enroll quickly given the high incidence of COVID-19, and initial results may be available later this year.